Celcuity Inc. (CELC)

Market Cap	5.96B +1,380.2%
Revenue (ttm)	n/a
Net Income	-177.04M
EPS	-3.79
Shares Out	48.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,892
Open	116.80
Previous Close	116.94
Day's Range	115.68 - 122.90
52-Week Range	7.61 - 123.26
Beta	0.42
Analysts	Strong Buy
Price Target	107.88 (-12.48%)
Earnings Date	May 13, 2026

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC
• Website: https://www.celcuity.com

Analyst Summary

According to 8 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $107.88, which is a decrease of -12.48% from the latest price.

Price Target

$107.88

(-12.48% downside)

Analyst Consensus: Strong Buy